Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline.
Conclusions: There is no evidence for or against the use of local or regional interventions other than transarterial chemoembolization for the treatment of intermediate- or advanced-stage hcc. Furthermore, there is no evidence to support the addition of sorafenib to any local or regional therapy. Sorafenib or lenvatinib are recommended for first-line systemic treatment of intermediate-stage hcc. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment. Antiviral treatment is recommended in individuals with advanced hcc who are positive for the hepatitis B surface antigen.
PMID: 32489260 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Cancer & Oncology | Carcinoma | Databases & Libraries | Gastroenterology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver Cancer | Study | Transplants